论文部分内容阅读
目的 :研究鞘内化疗联合全脑放疗治疗脑转移瘤的临床疗效及不良反应。方法 :治疗组 :鞘内注射氨甲蝶呤(MTX) 8mg/m2 ,同时行全脑放疗 ,总剂量 40 0 0cGy/4周。对照组仅给予单纯全脑放疗 ,方法同上。结果 :近期疗效 :治疗组有效率 :76.9% ,对照组 :69.2 % ,两者相比P >0 .0 5 ;远期疗效 :治疗组 (中位生存期和卡氏评分 )较单纯放疗有明显提高 ,P <0 .0 5 ,有统计学意义 ;毒副作用 :无明显差异。结论 :鞘内化疗联合放疗治疗脑转移瘤能够提高生活质量 ,延长生存期 ,值得推广应用。
Objective: To study the clinical effects and adverse reactions of intrathecal chemotherapy combined with whole brain radiotherapy in the treatment of brain metastases. Methods: The treatment group: intrathecal methotrexate (MTX) 8mg / m2, while the whole brain radiotherapy, a total dose of 40 0cGy / 4 weeks. The control group was given only whole brain radiotherapy, method Ibid. Results: The short-term curative effect: The effective rate of the treatment group was 76.9%, while that of the control group was 69.2%, P <0.05. The long-term effect: The treatment group (median survival and Karnofsky score) Significantly increased, P <0. 0 5, with statistical significance; side effects: no significant difference. Conclusion: The combination of intrathecal chemotherapy and radiotherapy for brain metastases can improve the quality of life and prolong survival, which is worth popularizing and applying.